Sunitinib Malate Capsule
Product Images NDC 42291-901

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sunitinib Malate (NDC 42291-901). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

12.5 (901 28)

Label for Sunitinib Malate Capsules 12.5 mg by AvKARE, showing NDC 42291-901-28. The label states 28 capsules per container, Rx only. It includes storage instructions, dispensing information, and the barcode. Manufacturer details and the AvKARE logo are present.*

FDA Label Image

25 (902 28)

The label for Sunitinib Malate Capsules 25 mg by AvKARE shows dosage strength prominently with 'Rx Only' and a package size of 28 capsules. It includes the NDC number 42291-902-28, usage and storage instructions, a barcode, and the AvKARE logo with manufacturing location Pulaski, TN.*

FDA Label Image

37.5 (903 28)

Packaging label for Sunitinib Malate Capsules 37.5 mg by AvKARE. The label indicates prescription use with a package size of 28 capsules. It includes barcode, storage instructions, dispensing guidelines, and manufacturer details along with a QR code and the AvKARE logo.*

FDA Label Image

50 (904 28)

Packaging label for Sunitinib Malate Capsules, 50 mg strength, oral dosage form, containing 28 capsules. The product is prescription-only (Rx Only) and manufactured by AvKARE. The label includes the NDC 42291-904-28 and a barcode.*

FDA Label Image

1 (Image 1)

Chemical structure of Sunitinib Malate showing the molecular arrangement of atoms including fluorine, nitrogen, oxygen, and methyl groups, along with the malate moiety. The diagram depicts the compound's detailed bonding and stereochemistry.*

FDA Label Image

1 (Image 2)

A Kaplan-Meier survival curve chart showing Time to Tumor Progression Probability (%) over Time (Weeks). It compares the progression for two groups: Sunitinib Malate (N=207) with a median time of 27.3 weeks, and Placebo (N=105) with a median time of 6.4 weeks. The chart includes a hazard ratio and statistical data related to these groups.*

FDA Label Image

1 (Image 3)

This Kaplan-Meier survival curve compares progression free survival probability over time (weeks) between 375 subjects treated with Sunitinib Malate and 375 subjects treated with IFN-α. The plot shows median progression free survival of 47.3 weeks for Sunitinib Malate and 22.0 weeks for IFN-α, with numbers at risk detailed below the x-axis.*

FDA Label Image

1 (Image 4)

A Kaplan-Meier curve chart depicting disease-free survival probability over time (years) comparing Sunitinib Malate and placebo groups. The graph shows survival percentages on the y-axis and time in years on the x-axis, with median disease-free survival of 6.8 years for Sunitinib Malate and 5.6 years for placebo. The chart includes hazard ratio, confidence interval, and p-value data for statistical comparison.*

FDA Label Image

1 (Image 5)

A Kaplan-Meier survival curve comparing progression-free survival probability over time in months for Sunitinib Malate versus placebo, including subject numbers at risk and statistical data such as hazard ratio and confidence interval.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.